A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus

Update Il y a 4 ans
Reference: EUCTR2005-000706-31

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.


Inclusion criteria

  • Systemic Lupus Erythematosus